Regenerative Medicine in 2021: A Year of Firsts and Records
The regenerative medicine and advanced therapies sector completed its best-ever six-month period of financing, raising $14.1B from January through June and reaching 71% of the record amount raised in all of 2020, according to the Alliance for Regenerative Medicine’s (ARM) H1 2021 Report.
Recordings Available: ARM’s Cell & Gene Webinar Series
This spring, ARM hosted experts on biotech fundraising, market access, value-based therapies, clinical trials amidst the pandemic, and cell therapies to treat COVID-19 as a part of a webinar series on timely sector issues.
ARM and NIIMBL Release Project A-Gene to Bring QbD Principles to Gene Therapy Manufacturing
The Alliance for Regenerative Medicine (ARM) and the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) today released Project A-Gene, a multistakeholder collaboration to incorporate Quality by Design (QbD) principles into a manufacturing case study of a viral vector commonly used in gene therapies.
ARM CEO Janet Lambert discusses milestones from the cell and gene therapy sector over the past year and gives an update on the current financial, clinical, and policy environment for these innovative therapies.
Potentially curative cell and gene therapies are changing the face of medicine and providing hope to patients where there was once none. But how will they be paid for? This webinar discusses the implementation of value-based payment models for innovative therapies.
This webinar highlights potential treatments for Acute Respiratory Distress syndrome (ARDS) in COVID-19 patients. Two therapeutic developers, Athersys and Pluristem Therapeutics, presented on their treatment approaches and plans for near term clinical trials.
ARM’s annual State of the Industry briefing provides an update on global financings, clinical development, public policy considerations, and other regenerative medicine sector trends. A recording of the presentation is available here.